Related Experiment Video
Updated: Jun 28, 2026
09:00
High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
Published on: October 31, 2012
Prophylaxis regimens for GVHD: systematic review and meta-analysis
R Ram1, A Gafter-Gvili, M Yeshurun
1Institute of Hematology, Davidoff Center Rabin Medical Center, Beilinson Hospital, Petah-Tiqva, Israel.
Bone Marrow Transplantation
|November 11, 2008
Summary
Methotrexate-cyclosporine (MTX-CsA) and MTX-tacrolimus are effective for preventing graft-versus-host disease (GVHD). MTX-tacrolimus may offer superior reduction in acute GVHD compared to MTX-CsA.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Graft-versus-host disease (GVHD) remains a significant challenge after allogeneic stem cell transplantation (Allo-SCT).
- Optimal prophylactic regimens for GVHD are debated, impacting patient survival and outcomes.
Purpose of the Study:
- To evaluate the survival benefit of different prophylactic regimens for acute GVHD (aGVHD).
- To compare the efficacy of various GVHD prophylaxis strategies in patients undergoing Allo-SCT.
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials (RCTs).
- Inclusion of trials assessing methotrexate (MTX), cyclosporine (CsA), tacrolimus, and steroids in GVHD prophylaxis.
- Pooled estimation of relative risks (RRs) for all-cause mortality (ACM), aGVHD, chronic GVHD, treatment-related mortality (TRM), relapse, and adverse events.
Main Results:
- MTX-CsA significantly decreased aGVHD compared to CsA alone (RR=0.52 (0.39-0.7)).
- MTX-tacrolimus showed no difference in ACM versus MTX-CsA but was superior in reducing aGVHD (RR=0.62 (0.52-0.75)) and severe aGVHD (RR=0.67 (0.47-0.95)).
- Addition of steroids to prophylactic regimens did not significantly affect outcomes.
Conclusions:
- Both MTX-CsA and MTX-tacrolimus are viable options for GVHD prophylaxis.
- MTX-tacrolimus may offer an advantage in reducing the incidence and severity of acute GVHD.
More Related Videos
08:05Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
Published on: March 17, 2020
08:04Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Published on: July 9, 2014
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
01:15Drug Dosage Regimen: Overview
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:27Cytomegalovirus Disease
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...